|
Oncogenes and Tumor Suppressors
Citations 231-240 of 795 total displayed.
|
Past content
(since May 2000):
|
A murine Mll-AF4 knock-in model results in lymphoid and myeloid deregulation and hematologic malignancy
- Weili Chen, Quanzhi Li, Wendy A. Hudson, Ashish Kumar, Nicole Kirchhof, and John H. Kersey
Blood 2006; 108: 669-677.
[Abstract]
[Full text]
[PDF]
Complex interaction of BCRP/ABCG2 and imatinib in BCR-ABL–expressing cells: BCRP-mediated resistance to imatinib is attenuated by imatinib-induced reduction of BCRP expression
- Takeo Nakanishi, Ken Shiozawa, Bret A. Hassel, and Douglas D. Ross
Blood 2006; 108: 678-684.
[Abstract]
[Full text]
[PDF]
OCT-1–mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib
- Deborah L. White, Verity A. Saunders, Phuong Dang, Jane Engler, Andrew C. W. Zannettino, Antony C. Cambareri, Steven R. Quinn, Paul W. Manley, and Timothy P. Hughes
Blood 2006; 108: 697-704.
[Abstract]
[Full text]
[PDF]
Biologic pathways associated with relapse in childhood acute lymphoblastic leukemia: a Children's Oncology Group study
- Deepa Bhojwani, Huining Kang, Naomi P. Moskowitz, Dong-Joon Min, Hokyung Lee, Jeffrey W. Potter, George Davidson, Cheryl L. Willman, Michael J. Borowitz, Ilana Belitskaya-Levy, Stephen P. Hunger, Elizabeth A. Raetz, and William L. Carroll
Blood 2006; 108: 711-717.
[Abstract]
[Full text]
[PDF]
Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results
- Timothy Hughes, Michael Deininger, Andreas Hochhaus, Susan Branford, Jerald Radich, Jaspal Kaeda, Michele Baccarani, Jorge Cortes, Nicholas C. P. Cross, Brian J. Druker, Jean Gabert, David Grimwade, Rüdiger Hehlmann, Suzanne Kamel-Reid, Jeffrey H. Lipton, Janina Longtine, Giovanni Martinelli, Giuseppe Saglio, Simona Soverini, Wendy Stock, and John M. Goldman
Blood 2006; 108: 28-37.
[Abstract]
[Full text]
[PDF]
Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis
- Neil P. Shah, Francis Y. Lee, Roger Luo, Yibin Jiang, Marjolein Donker, and Cem Akin
Blood 2006; 108: 286-291.
[Abstract]
[Full text]
[PDF]
c-Myb is an essential downstream target for homeobox-mediated transformation of hematopoietic cells
- Jay L. Hess, Claudia B. Bittner, Deniz T. Zeisig, Christian Bach, Uta Fuchs, Arndt Borkhardt, Jon Frampton, and Robert K. Slany
Blood 2006; 108: 297-304.
[Abstract]
[Full text]
[PDF]
BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance
- Mateusz Koptyra, Rafal Falinski, Michal O. Nowicki, Tomasz Stoklosa, Ireneusz Majsterek, Margaret Nieborowska-Skorska, Janusz Blasiak, and Tomasz Skorski
Blood 2006; 108: 319-327.
[Abstract]
[Full text]
[PDF]
Role of transforming growth factor- in hematologic malignancies
- Mei Dong and Gerard C. Blobe
Blood 2006; 107: 4589-4596.
[Abstract]
[Full text]
[PDF]
Infants with acute lymphoblastic leukemia and a germline MLL gene are highly curable with use of chemotherapy alone: results from the Japan Infant Leukemia Study Group
- Jun Nagayama, Daisuke Tomizawa, Katsuyoshi Koh, Yoshihisa Nagatoshi, Noriko Hotta, Tomoko Kishimoto, Yoshihiro Takahashi, Tomoko Kuno, Kanji Sugita, Takashi Sato, Kohji Kato, Atsushi Ogawa, Tatsutoshi Nakahata, Shuki Mizutani, Keizo Horibe, and Eiichi Ishii
Blood 2006; 107: 4663-4665.
[Abstract]
[Full text]
[PDF]
|
|
